ahead esg performance report global biopharma company purpose unite science technology talent ahead disease aim positively impact health billion people end bold ambition patient reflect commitment growth stepchange performance company outstanding people thrive responsible business mean get ahead disease report right way need consider ceo statement environmental social governance esg impact lab patient s esg approach embed strategy support sustainable performance longterm growth help build trust progress focus area deliver return stakeholder reduce risk access operation deliver positive social impact global health health security report environment report publish performance diversity equity inclusion esg focus area report include report ethical standard sustainability accounting standard board sasb global product governance report initiative gri submit annual un global compact communication progress ungc cop appendix find public position range issue materiality assessment public policy gskcom publish information people disclosure gskcom include gri sasb index sustainable development goal esg report criterion engagement patient organisation independent limited assurance report engagement healthcare professional landmark year gsk follow demerger trade association memberships consumer healthcare business form haleon july charitable partnership fullyfocuse biopharma company datum report exclude previous consumer healthcare business specify external benchmarking detailed perform key esg rating ftsegood member ftsegood index frequently ask investor cdp climate change b water security forest access medicine rank st access medicine palm oil b forest timber index industry leader antimicrobial sustainalytic low risk rating resistance benchmark msci aa rating sp global corporate sustainability assessment rank moodys esg solution rank nd nd pharmaceutical industry score pharmaceutical sector february include djsi world iss corporate rating b rating europe indice cautionary statement document contain forwardlooke statement forwardlooke forwardlooke statement result new information statement group current expectation forecast future event future event investor consult additional investor identify statement fact relate disclosure group document publish strictly historical current fact use word anticipate andor file securities exchange commission investor believe estimate expect intend plan project target locate note disclosure accordingly word term similar meaning connection discussion future assurance give particular expectation meet operate financial performance particular include statement investor caution place undue reliance forwardlooke relate future action prospective product product approval future statement forwardlooke statement subject assumption inherent performance result current anticipate product sale effort risk uncertainty relate factor expense outcome contingency legal proceeding dividend group control precise estimate group caution investor payment financial result accordance legal number important factor include report cause actual regulatory obligation include market abuse regulation uk result differ materially express imply forward list rule disclosure guidance transparency rule look statement financial conduct authority group undertake obligation update gsk esg performance report march ceo statement please provide report esg performance gsk purpose unite science technology talent include performance strong progress ahead disease vaccine medicine access initiative reach million building trust operate responsibly integral people low income country strategy culture ultimately support return progress global health pipeline asset priority shareholder reduce risk help people thrive disease include malaria tb deliver sustainable health impact scale rd project relevant amr target pathogen esg focus core area access healthcare global deem critical urgent cdc health health security environment diversity equity phase iii trial start diversity plan enrol inclusion ethical standard product governance affect disease study area address matter business improvement gender ethnicity representation stakeholder great leadership positive impact society urgent challenge reduction indirect carbon emission late available scope datum set progress make area delivery target reduce water use operation supplement annual report hope information level transparency helpful particularly investor employee complete mandatory training strengthen measurement report gsk overall esg performance year introduce new esg esg performance continues recognise rank performance rate st access medicine index th consecutive time rank nd sp global corporate sustainability new rating corporate kpis measure assessment pharmaceutical industry maintain progress key metric align focus topquartile position msci iss corporate rating area include metric develop sustainalytic esg rating stakeholder input assess aggregate single overall performance score please report proud progress approach esg gsk performance track detail constant review responsible business find page static requirement operating environment continue change pace continue adapt respond proactively change approach ensure gsk continue deliver strong esg performance alongside broad performance company emma walmsley chief executive officer gsk esg performance report march approach access global health environment dei ethical standard product governance appendix approach esg integral strategy purpose impact lab patient esg focus area esg governance deliver purpose build trust embed esg performance monitor regularly board esg identify esg focus level corporate responsibility committee crc gsk area address material business leadership team glt crc oversee progress issue matter stakeholder focus area commitment include performance core strategy area meet expectation stakeholder great positive impact society urgent glt senior management responsible delivery challenge focus area focus area report regularly crc access healthcare progress page annual report global health health security esgaligne remuneration environment diversity equity inclusion dei remuneration committee support crc introduce esg performance measure ethical standard short longterm incentive plan reward delivery key product governance esg commitment esg element consist human capital approach guide extensive stakeholder engagement management form diversity equity inclusion key issue relevant industry company form annual bonus opportunity glt result recent materiality assessment reaffirm climate net zero nature net positive ambition form material issue business align longterm incentive plan opportunity senior leader esg focus area aware metric align esg performance rating annual responsible business static requirement operating report information environment continue change pace continue adapt respond proactively change approach ensure gsk continue deliver strong esg performance gskcom materiality assessment esg performance rating support integration esg strategy delivery assess performance esg performance measurable verifiable glt accountable deliver progress metric introduce new esg performance rating rating regularly review performance board crc corporate kpis measure progress key metric individual metric assess track metric meet align focus area include exceed track work metric metric summarise page metric achieve track metric miss develop stakeholder input understand addition order calculate overall esg performance key issue industry company commit rating performance metric aggregate single ensure esg performance rating respond score illustrate track track work stakeholder expectation continue review metric track rating define business external expectation change create esg performance rating management seek track metric track metric track work metric track track work define ensure standardised approach consistently future year track metric track ambitious achievable externally assure meaningful stakeholder gsk esg performance report march approach access global health environment dei ethical standard product governance appendix approach continue esg performance rating esg performance rating track base performance metric meet exceed assessment performance annual target review overall esg performance rating score externally assure esg focus area commitment metric performance access product available valuebase price sustainable business implement access read strategy increase use medicine vaccine treat protect underserved people performance metric highlight focus area develop externally publish pricing publish pricing access principle guide access principle approach responsible pricing progress goal reach billion reach million people people low income country product product supply additional million dose albendazole global health develop novel product technology treat prevent priority disease include pandemic threat health performance metric highlight focus area security progress global health pipeline asset progress global health pipeline asset address read address priority disease priority disease include malaria tuberculosis tb positive phase iia study result new firstinclass candidate medicine patient tb australian therapeutic good administration approve use singledose tafenoquine child aged combination chloroquine radical cure p vivax malaria fda approve triumeq pd increase age appropriate treatment option child live hiv environment commit net zero nature positive healthy planet ambitious goal set read performance metric highlight focus area climate reduce scope carbon operational operational emission reduction scope emission marketbase emission reduce scope value chain emission industrialisation green ventolin initiate clinical nonclinical datum available support good progress reformulate ventolin regulatory submission reduce climate impact meter percentage carbon offset volume project pipeline dose inhaler clinical trial successful water gsk site supplier compliant average percentage gsk site wastewater discharge limit supplier compliant wastewater active site good water steward line pharmaceutical ingredient limit percentage alliance water stewardship definition supplier compliant amr industry alliance common antibiotic manufacturing achieve target reduce overall water framework discharge limit use baseline review target waste material complete baseline biodiversity assessment operational waste material reduction site site biodiversity highrisk material implement sustainable number highrisk material implement source roadmap sustainable source roadmap million figure include people reach synflorix rotarix cervarix opv mosquirix vaccine people access generic dolutegravir product voluntary licensing agreement include people reach albendazole assessment gsk cope emission cover emission direct combustion fuel site generate heat electricity emission sale fleet vehicle fugitive loss propellant manufacturing inhaler loss refrigerant gskowne ancillary equipment emission onsite waste treatment scope emission include purchase electricity steam compress air chill water percentage mtco offset volume project pipeline gsk esg performance report march approach access global health environment dei ethical standard product governance appendix approach continue esg focus area commitment metric performance diversity equity create diverse equitable inclusive workplace enhance recruitment diverse patient population inclusion clinical trial support diverse community read performance metric highlight focus area phase iii trial initiate phase iii trial initiate proactive proactive plan place design enrol demographic plan place appropriately diverse trial participant consistent woman vpandabove role globally disease epidemiology compare performance aspiration fair ethnically diverse leader vp equitable opportunity level increase percentage black woman hold vpandabove african american hispanic latinx vpand role globally end leader ethnically diverse leader uk ethnically diverse leader role vp increase role vp percentage percentage black african american black vpandabove leader remain hispanic latinx vpandabove leader year year significantly exceed target increase spend ethnically diverse leader certify usbased diverseowne supplier role vp uk increase percentage black vpandabove leader year year improve yearonyear spend certify usbased diverseowned supplier ethical promote ethical behaviour business support employee right thing working standard supplier share standard operate responsible way read performance metric highlight focus area employee complementary worker achieve overall completion gsk mandatory complete gsk mandatory training training employee complete percentage employee believe training meet completion rate speak thing not feel right complementary worker general industry benchmark employee believe speak number employee leave gsk employment thing feel right misconduct month versus number employee leave gsk employment threeyear roll average misconduct increase result enhance direct highrisk supplier achieve gsk risk identification target intervention minimum ecovadi score improvement direct highrisk supplier achieve minimum plan place ecovadis score product commit maintain robust quality safety process datum new technology responsibly governance performance metric highlight focus area read average number critical major finding receive warning letter fda critical fdamhraema regulator finding mhra ema regulator percentage inspection regulator inspection regulator critical critical finding official action indicate finding official action indicate number fda warning letter continue reduce level recall total number class iii external product recall market class product recall market few class ii iii recall register disclose human subject research protocol summary gsk product specifically register protocol summary result available list study summary study initiate disclose datum share setup gsk trial result summarie study result register general industry benchmark accord research kornferry n continue embed great focus use risk analytic monitoring align increase level business activity enhance risk identification target intervention additionally focus closure case result decrease open case year end compare prior year correlation rise number employee dismiss agree leave company voluntarily result misconduct gsk esg performance report march approach access global health environment dei ethical standard product governance appendix approach continue put people heart success culture focus diversity equity inclusion commit make gsk place people continue focus build diverse thrive culture ambitious patient organisation equitable inclusive culture accountable impact right thing mean feel welcome value include deliver support people thing well fast focus leadership representation aspiration implement matter mean set clear objective annual dei training invest development tool accountability result give support build inclusive leader support awardwinne space need succeed mean leadership development programme accelerate difference responsibly care integrity people patient support woman ethnically diverse leader world count continue evolve people policy process practice support recruitment retention development dedicate significant leadership energy diverse workforce detail aspirational target dei bring life ahead purpose strategy culture people business supplier find gsk place real emphasis individual ownership culture small change need drive performance choice reality change support team conversation guide simple tool globally support performance choice approach hybrid work well fast decision make great clarity officebase role quarter people accountabilitie ambitious focused objective continue allow find right balance onsite remote work framework balanced drive collective june introduce code set culture individual performance support individual commitment gsk people flexibility support personal wellbeing driving performance deliver ambition right way gsk people sign make attractive employer code annually personally commit m year clear expectation gskcom code spend time person help continue build sense community connectedness enable development make gsk place people thrive well achieve ahead ambition core ahead ambition gsk place people thrive people thrive individual develop outstanding people believe common theme matter committed develop outstanding people give firstly belief purpose desire live culture people opportunity grow gsk people expect contribute deliver ambition secondly feel include agree development plan regardless grade role able opportunity grow underpin robust conversation understand support feedback space need succeed finally space support need succeed continue feel good positive mental physical financial social invest development initiative training wellbeing require gsk place people feel access grow campus central welcome value environment include policy platform training knowledge sharing workplace way work wholeheartedly enable support person deliver well redesign talent framework focus review people performance living culture support people manager future potential give simple assessment process people manager play crucial role help team line culture support place good people thrive bring culture life expect people manager critical role strong diverse succession plan motivate focus care develop team allow spend time development action year deliver line leader training anchor plan process area population addition launch new senior leader programme lead leader build leadership development senior level organisation preparation bring people manager virtual event bring life big priority support manager set focus ambitious objective team align innovation performance trust culture priority gsk esg performance report march approach access global health environment dei ethical standard product governance appendix approach continue health wellbeing improvement recognise reward people announce improvement health wellbeing share success recognise reward people benefit well support people different life stage progress sure offering fair inclusive continue important culture addition include new global minimum standard week parental bonus scheme reward performance company leave primary secondary carer form family year award population extra ahead new global minimum standard care family member award deliver exceptional performance end life health emergency insure benefit line culture people identify miss include sex partner possible new financial performance deliver objective wellbee service mental health training available live culture year addition annual bonus longterm incentive structure give special thank people exclude glt allow recognise real november give onetime discretionary payment time achieve preparation separation people feel great impact rise costof unprecedented transformation gsk live challenge payment give half receive oneoff week salary march separate global workforce country consistent criterion bonus payout determine eligible country remain energised continually live evolve culture understand people experience gsk line internal external environment regularly measure people experience gsk include everyone objective start leadership team progress culture focus area place work member ambitious goal embe grow culture include annual survey employee feature question show act day engagement confidence inclusivity culture focus area trust priority run series pulse survey year statistically significant population timely insight culture progress hot topic moment year progress demonstrate increase engagement confidence delivery ambition positive trend ambition patient accountability impact right thing measure inclusion measure effectiveness global manager population team provide feedback annual survey manager receive anonymised aggregate feedback effectiveness motivate team focus people matter lead care inclusive leadership support performance development manager rate highly effective report gsk esg performance report march approach access global health environment dei ethical standard product governance appendix access ambition positively impact health billion people end achieve develop vaccine medicine make available responsible pricing strategic access programme partnership bn people reach low country cover viiv vaccine supply low income country healthcare paediatric price gavi vaccine product voluntary licensing agreement alliance generic manufacturer commitment assess performance product available valuebase price develop externally publish pricing access principle sustainable business implement access strategy progress goal reach billion people increase use medicine vaccine treat low income country product protect underserved people aim vaccine medicine available discovery development medicine vaccine responsible price accessible patient sustainable complex take significant time risk investment business make sure underserved people succeed follow set pricing access principle publish treat protect access strategy time help balance right recognition action take ahead disease responsible pricing sustainable profitable business rank access medicine index allow reinvest financial return future innovation eighth consecutive time ensure people access medicine vaccine gskcom position pricing access pricing access principle put right value innovation pursue area unmet medical need deploy cuttingedge recognise health inequity include high income science advanced technology develop effective country help uninsured underinsured patient navigate medicine vaccine speed scale precision healthcare system programme increase access provide financial disease management support example compare offer available patient gsk viiv healthcare patient generate evidence clinical trial realworld assistance program foundation provide prescribe setting establish add value medicine medicine vaccine lowincome vaccine principle ensure set price uninsured underinsured medicare patient portfolio line benefit bring patient health system measure clinical economic social outcome year combine average net price discount rebate allowance pharmaceutical consideration socioeconomic status country vaccine portfolio increase average list ensure affordability availability product include price increase compare list industry tiere pricing base world bank income classification demonstrate responsible pricing decision vaccine tender collaborate global health partner past year average net price product increase impact low income country example decrease annually average list price rise supply vaccine dose low price gavi compare list industry operate international alliance improve access vaccine country robust pricing approval develop access plan low gdp viiv healthcare provide nonprofit pricing inform payer work create stability public health system lowincome develop predictability payer business engage proactively subsaharan african country antiretroviral medicine upcoming product launch plan budget treat people live hiv innovation prevent adjust price account inflation hiv transmission million figure include people reach synflorix rotarix cervarix opv mosquirix vaccine people access generic dolutegravir product voluntary licensing agreement include people reach albendazole assessment gsk ndustry average source drug channel annual brandname drug list change report gsk esg performance report march approach access global health environment dei ethical standard product governance appendix access continue reach patient low income country ambitious patient develop access strategy hiv real difference nearly billion people support production generic drug improve globally lack access essential medicine vaccine access viiv healthcare medicine patent pool prevent treat disease relieve suffer improve quality mpp sign new voluntary licensing agreement allow life prevent death goal reach billion people generic manufacturer develop manufacture supply low income country product end cabotegravir longacte hiv preexposure prophylaxis access initiative voluntary licensing donation aim enable access drug develop lowincome work gavi vaccine alliance reach low middleincome subsaharan african country million people product supply additional come year meantime viiv work stakeholder million dose albendazole include global health agency nongovernmental decade work partner strengthen organisation ngo government community partner healthcare system key increase access medicine plan support successful introduction cabotegravir low income country partner longacte preexposure prophylaxis national right capability geographic reach local knowledge programme viiv manufacture product innovation patient medicine lowincome country viiv healthcare voluntary licensing agreement file patent medicine enforce historic patent generic manufacturer produce sell lowcost single let company manufacture supply generic fixeddose combination product contain hiv medicine version gsk medicine country dolutegravir adult low middleincome country direct licence mpp vaccine similar agreement generic manufacturer child important work organisation like cover country result voluntary licence gavi vaccine alliance help reach agreement million people live hiv vulnerable people pressure place healthcare system country access generic product contain dolutegravir low income country covid pandemic result end people live hiv reduction routine immunisation put million children antiretroviral low middleincome country health risk viiv healthcare donate pack partner gavi foundation antiretroviral medicine ngo partner national hiv reserve low vaccine price gavi similar aid programme support people live hiv organisation pass milestone supplying impact conflict ukraine viiv provide gavi billion vaccine positive action programme support communitybase organisation humanitarian response partnership include supply cervarix critical vaccine activity ukraine surround country low income country address cervical cancer host refugee supply million dose pneumococcal vaccine synflorix gavieligible country low positive action viiv healthcare community grantgive price rotarix vaccine rotavirus reach child programme celebrate th anniversary gavieligible country gavi country yearlong campaign showcase people heart march synflorix offer programme partner implementation rotarix humanitarian mechanism civil society progress collaboration invest organisation serve refugee work emergency million reach approximately people situation longstanding supplier oral polio provide grant country vaccine opv unicef supply million dose help eradicate polio malaria work partner million child africa neglect tropical disease receive dose malaria vaccine donate billion albendazole tablet mosquirix rtssa e develop year include million support effort gsk partner mosquirix vaccine end lymphatic filariasis commonly know elephantiasis clinical trial show acceptable safety profile reduce morbidity intestinal worm soiltransmitte feasible deliver substantially reduce deadly severe malaria helminth schoolage child extend child september award pre soiltransmitte helminth commitment include preschool qualification vaccine follow rigorous regulatory child additional commitment donate process ensure meet standard quality safety albendazole treatment echinococcosis accord efficacy suitable target population late datum benefit million prerequisite un agencies procure vaccine people programme begin million people important step roll country moderate high treat lymphatic filariasis programme p falciparum malaria transmission country include million child gsk esg performance report march approach access global health environment dei ethical standard product governance appendix access continued gsk path bharat biotech agree product transfer whocoordinate malaria vaccine implementation help ensure longterm supply rtss malaria vaccine programme mvip ghana kenya malawi june commit supply million dose gsk commit supply million dose year addition donation million dose adjuvant rtss malaria vaccine strengthen healthcare system longstanding partnership amref health africa partnership save child aim cut number continue tuberculosis tb malaria programme child die preventable treatable disease ethiopia kenya launch improve education strengthen healthcare system drive rd address critical diagnosis treatment underserved community knowledge gap create systemic change children health complement specific paediatric hiv testing component global level support save children emergency end fund viiv healthcare positive preparedness response capability invest datum action programme work healthcare worker analytic early action protocol partnership manager strengthen healthcare system improve reach million child globally country laboratory testing diagnostic surveillance information train healthcare worker support system supply chain community healthcare worker tb malaria programme healthcare gsksave child partnership begin work worker train country un green climate fund project malawi kenyan subcountie support programme senegal support national government healthcare worker able effectively diagnose objective address health impact climate change manage tb malaria uptake contribute resilient healthcare system preventative service community ethiopia integrate collaboration bill melinda gates ceo tb malaria hiv care mean woman child roundtable programme work jj novartis eli benefit screen disease single lilly pfizer train healthcare worker african country antenatal care appointment programme train healthcare worker bring amref health africa cognizant gsk technology partner integrate digital tool well plan identify respond healthcare worker training need community level platform successfully pilot hope reach thousand healthcare worker subsaharan africa quality training help meet need million people community investment cash product inkind time management cost total community investment value gsk medicine vaccine provide patient assistance program foundation pr metric contribute esg performance rating metric datum externally assure product donation value global average cost good report yearend result employee volunteer significantly impact covid pandemic product donation include total community investment figure report gsk esg performance report march approach access global health environment dei ethical standard product governance appendix access continue pricing year change list net price change combine average net price pharmaceutical vaccine portfolio previous year change average list price previous year year list net price compound annual growth rate change net price discount rebate allowance product past year change average list price past year product reach dose supply low income country dose synflorix vaccine supply gavi pr dose rotarix vaccine supply gavi pr dose cervarix vaccine supply gavi pr doses opv vaccine supply unicef pr doses mosquirix rtssa e vaccine supply mvip pr albendazole tablet donate help eliminate lymphatic filariasis pr albendazole tablet donate help treat intestinal worm pr total dose supply pr product reach people reach low income country people access generic dolutegravir product voluntary licensing agreement estimate child reach synflorix gavi estimate child reach rotarix gavi estimate girl reach cervarix gavi estimate people reach opv unicef estimate people reach mosquirix rtssa e mvip total people reach people reach healthcare access programme people access healthcare service worker educational session work save child people access healthcare worker service facility result bill melinda gates ceo roundtable programme people reach viiv healthcare positive action child fund grant people reach viiv healthcare positive action strategy grant people reach patient assistance program pr metric contribute esg performance rating metric datum externally assure calculate gsk viiv healthcare product product donation include total community investment figure report product donation value global average cost good report yearend result chronic ongoing treatment cumulative number people access dolutegravir annual datum report figure estimate base sale generic dolutegravirbase product voluntary licensing agreement update methodology include sale generic dolutegravirbase product previous year sale tld tenofovir disoproxil lamivudine dolutegravir included form large majority generic sale worldwide time total low figure report esg performance report overestimate stock building pandemic w e healthcare access programme end people access malaria comic relief partnership healthcare worker train partner people access healthcare worker service facility result healthcare worker training programme ur total lower previous year partnership programme conclude bill melinda gates ceo roundtable programme fund pharmaceutical company gsk jj novartis lilly pfizer bill melinda gates foundation funder organisation equal contributor reach number total programme reach divide r datum collect provide grantee datum capture month cycle grantee report month previous month final datum available june report update reflect actual figure gsk esg performance report march approach access global health environment dei ethical standard product governance appendix global health health security use expertise address big health challenge underserve people world bn investment rd help global health pipeline asset rd project relevant ahead infectious address priority antimicrobial resistance disease low income disease progress pipeline country commitment assess performance develop novel product technology treat progress global health pipeline asset address prevent priority disease include pandemic threat priority disease unique important role play improve health worldleade dedicated global health innovation patient world help world prepare hub vaccine medicine develop product future health security challenge determine help technology prevent treat priority infectious disease change trajectory high burden infectious disease progress global health pipeline asset disproportionately affect underserved people world address priority disease exceed target trap cycle disease poverty wellfunctione healthcare system critical enable deliver goal dedicate global health unit access right treatment vaccine work success measure health impact profit include longterm partner help strengthen healthcare system low viiv healthcare work potential vaccine income country drive local need work increase medicine target high burden infectious disease underserve people access medicine vaccine put unique rd scientific expertise work address describe access world big health challenge include tuberculosis tb malaria antimicrobial resistance amr global health rd billion accelerate rd want discover shorter simple safe treatment tb alongside partner publicprivate june gsk include viiv healthcare announce research consortium continue progress pipeline billion investment rd help ahead infectious novel tb medicine announce positive phase iia disease low income country year investment study result gsk new firstinclass candidate support rd new medicine vaccine prevent medicine patient tb result study demonstrate treat tb malaria hiv enteric disease neglect tropical potential candidate component disease reduce amr simple treatment regimen future partnership help fund goal end hiv aid develop bioversys university lille innovative medicine enable access innovative treatment prevention initiative imi project trictb successfully complete option advance industryleade pipeline vaccine phase trial bvlgsk potential help include firstinclass vaccine invasive nontyphoidal tackle drug resistance boost activity exist salmonellosis shigellosis rd investment aim reduce antibiotic threat amr gsk industry leader publicprivate research consortium support imis amr accelerator eratb tackle tuberculosis unitetb aiming accelerate rd new tb tb responsible million death make drug treatment regimen drugresistant drug world secondleade cause death infectious disease sensitive tb covid gsk esg performance report march approach access global health environment dei ethical standard product governance appendix global health health security continue consortium aim enable progression bettertolerate fda approve triumeq pd dispersible single drug regimen short duration tb patient worldwide tablet formulation contain dolutegravir child weigh goal improve quality life life expectancy kg increase ageappropriate treatment project bring expertise public sector industry option child live hiv end academic partner significantly reduce development time committee medicinal product human use chmp preclinical candidate pharmaceutical company ema issue positive opinion recommend marketing authorisation triumeq pd child kg tb candidate vaccine mase demonstrate potential reduce active tb pulmonary disease adult address enteric disease neglect latent tb infection phase llb trial sub license bill melinda gates medical research institute tropical disease continue development major step tb global health rd centre research prevention year partnership exemplify potential solution enteric disease neglect tropical gsk approach global health rd unique contribution disease scientist look range disease scientific expertise focus research early invasive nontyphoidal salmonella typhoid paratyphoid fever development partner worldleading organisation group streptococcus visceral leishmaniasis chaga disease funder late development manufacturing access lymphatic filariasis soiltransmitte parasite dengue fever vaccine reach patient scale invasive nontyphoidal salmonella lifethreatening child africa key driver amr protect child malaria innovative vaccine technology partnership university malaria complex disease cause plasmodium parasite oxford vaccint develop potential candidate vaccine different type plasmodium parasite know generalised module membrane antigen technology infect human p falciparum prevalent subsaharan involve manipulate bacteria cell produce vaccines africa p vivax common south southeast asia manufacture scale costeffectively lowincome latin america know tool country ahead malaria particularly grow resistance continue invest generation transformative tool support scientific research capacity africa partner ve bring product prevention help support global rd december announce treatment malaria market world vaccine fourth proposal africa open lab malaria access singledose radical proposal aim african earlycareer scientist base cure p vivax malaria subsaharan africa focus infectious disease disproportionately affect subsaharan population march australian regulator therapeutic good malaria tb neglect tropical disease ambition administration approve use singledose medicine support african earlycareer scientist accelerate progress tafenoquine child aged combination get ahead major global health challenge help chloroquine radical cure p vivax malaria treatment develop generation african scientific leader target liver stage disease prevent relapse follow africa ncd open lab singledose radical cure develop gsk fund research project focus noncommunicable partner medicine malaria venture develop dispersible disease tablet formulation easy child hiv collaboration action million people live hiv globally live low middleincome country end generic dolutegravir dispersible tablet mg formulation specially develop child live hiv roll country year generic formulation receive tentative fda approval president emergency plan aid relief scheme facilitate innovative publicprivate partnership viiv clinton health access initiative unitaid generic manufacturer sublicence medicine patent pool provide technology transfer knowhow regulatory planning support second publicprivate partnership ongoing accelerate generic development introduction generic dolutegravirabacavirlamivudine dispersible tablet formulation gsk esg performance report march approach access global health environment dei ethical standard product governance appendix global health health security continue strengthen health security factor jeopardise health security provide clear guidance manufacturer global new emerge infectious disease rise amr antibiotic supply chain help ensure antibiotic climate change nature loss pose significant risk responsibly compliance scientifically robust discharge limit scientific knowhow collaborate help world well prepare future health challenge gskcom position antimicrobial resistance get ahead antimicrobial resistance future pandemic preparedness amr pose urgent threat public health study publish help preempt respond pandemic lancet analyse datum work government stakeholder strengthen country territory show million death global preparedness mean draw directly attributable bacterial amr great toll learn covid previous outbreak champion hiv malaria get ahead infectious disease innovation promote sustainable approach impend threat like amr help protect life livelihood biopharmaceutical sector public health healthcare system july gsk major biopharmaceutical rd expertise partnering amrfocuse company sign berlin declaration set organisation carbx drive innovation industry vision equitable access future pandemic prevention treatment rd project declaration state sector willingness reserve medicine vaccine relevant amr range allocation realtime production medicine vaccine early latestage development include gepotidacin distribution priority population determine health novel oral antibiotic treatment authority future pandemic dependent factor uncomplicate urinary tract infection year strong healthcare system recipient country announce exclusive licence agreement spero commit worldclass global vaccine therapeutic tebipenem hbr latestage antibiotic manufacture network support pandemic preparedness treat complicated urinary tract infection project response gsk conclude series contract target pathogen deem critical urgent provide million dose pandemic center disease control prevention influenza vaccine government world february annual report rd pipeline extend pandemic influenza vaccine stockpile surveillance central tackle amr share data contract united states government follow longrunne survey antibiotic resistance soar renew agreement june supply pandemic study track communityacquire respiratory infection influenza vaccine july contract new amr register develop vivli continue government canada seasonal pandemic share new datum available initiative help build influenza vaccine sign agreement europe collective understanding pathogen evolve reservation future production supply pandemic need protect influenza vaccine continue partner biomedical advanced research development authority promote effective stewardship antibiotic barda manufacture assess safety enable access continue train healthcare immunogenicity pandemic influenza vaccine candidate professional world prescribing antibiotic appropriately importance surveillance gskcom position pandemic preparedness study support responsible manufacturing antibiotic work amr industry alliance set global limit wastewater antibiotic discharge factory environment work alliance publish new antibiotic manufacturing standard global health pipeline asset priority disease number asset progress global health pipeline address priority disease pr pr metric contribute esg performance rating metric datum externally assure gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continue work hard protect environment partnership ve set clear measurable target help achieve goal reduction scope gsk site complete gsk site supplier carbon emission compare baseline biodiversity compliant wastewater assessment discharge limit commitment commit net zero nature positive healthy planet water ambitious goal set average percentage gsk site supplier compliant wastewater active pharmaceutical ingredient assess performance limit percentage supplier compliant climate amr industry alliance common antibiotic manufacture operational emission reduction scope marketbase framework discharge limit emission waste material industrialisation green ventolin initiate clinical operational waste material reduction site nonclinical datum available support regulatory submission biodiversity percentage carbon offset volume project pipeline number highrisk material implement sustainable source roadmap recognise world climate nature crisis pose achieve goal support longterm value creation build urgent threat human health worsen impact disease trust stakeholder reduce risk operation put healthcare system pressure commit require collaborate patient supplier work net zero nature positive healthy planet regulator peer integrate sustainability ambitious goal set goal cover operation ensure delivery entire value chain drug discovery disposal g skcom position environmental sustainability environmental product invest protect restore nature action report time investing ahead health impact climate change develop manufacture new medicine vaccine disease affect climate change work partner improve healthcare system resilience climate change climate set clear pathway net zero impact climate comply standard change require ambitious goal plan carbon reduction pathway reduction offset addition set longerterm target gsk set carbon ambition net zero impact reduce carbon emission climate plan meet goal aim remainder tackle highquality offset carbon reduction scope baseline remain offset investment highquality sbti accredited carbon target set prior naturebase solution demerger align oc pathway reduction pathway significantly ambitious sbti science base target initiative sbti publish netzero standard minimum requirement halve emission new carbon netzero standard aim address stakeholder concern inconsistent methodology definition net zero currently seek reaccreditation sbti target fullyfocuse biopharma company submit target verification sbti netzero standard gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continue supply chain emission value chain carbon footprint approximately total emission footprint come good service buy september scope emission operation launch sustainable procurement programme scope emission supplier require supplier action carbon power heat scope emission people product transport water waste sustainable deforestationfree metereddose inhaler source material thing scope emission require disclose emission set carbon reduction target align oc switch renewable power heat target new programme actively support supplier reduction carbon emission investment nature education adoption new environmental base solution remain footprint sustainability measure october gsk supplier scope forum attend supplier present renewable electricity scope sustainability plan clear expectation available net zero emission value chain support supplier scope continue build capability procurement function g skcom net zero pathway integrate sustainability include tender question contractual provision performance metric manage operational footprint supply chain emission share challenge reduce scope carbon emission industry sector collaborating find share solution compare primarily increase example participate manufacture initiative use renewable electricity continue delivery energy industry peer encourage supplier efficiency site installation new solar measure manage reduce emission supplier panel upgrade lighting replace chiller reduce register platform account threequarters use ozonedeplete refrigerant example site emission purchase good manufacture irvine scotland closedloop heating system helped drive codevelope activate programme reduction operating cost onsite renewable biogas found company help active pharmaceutical ingredient provide energy end api supplier gain access green funding practical member commit source support accelerate decarbonisation initiative renewable electricity reach work peer energize increase programme encourage use renewable energy member ev commit install pharmaceutical sector supply chain supplier charge infrastructure site transition sale fleet form energize buyer cohort purchase lowcarbon vehicle october hybrid terawatthour renewable electricity fully electric vehicle fleet sustainable market initiative health system charger instal site number charger task force ceo seven global healthcare increase location company task force announce joint action nearterm emission reduction target accelerate reduce value chain emission delivery net zero healthcare system addressing emission follow demerger consumer healthcare business supply chain patient care pathway clinical trial restate value chain carbon footprint baseline year latest available datum scope emission use product emission reduce compare reduction use medicine vaccine patient makes reflect evolution product portfolio total climate impact predominantly propellant meter dose inhaler asthma chronic obstructive pulmonary disease invest rd programme reduce greenhouse gas emission vital medicine good progress reformulation ventolin reduce climate impact clinical trial successful climaterelated financial disclosure page annual report disclosure climate risk resilience line task force climate relate financial disclosure tcfd framework arget measure baseline previously state net zero new longerterm target align sbti netzero standard definition net zero gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continue nature commit work goal net material circular economy positive impact nature reduce environmental target impact water waste material biodiversity zero operational waste include eliminate singleuse investing protect restore nature plastic protect nature play vital role protect human health environmental impact reduction product habitat degradation increase risk new human pathogen package pandemic emerge natural world provide waste reduction supply chain ingredient exist medicine inspiration new one continue reduce waste site make good progress meet water waste increase material recover circular material biodiversity target route like reuse recycle example site company trial science base target network nature introduce recycle chemical container sbtn methodology well understand impact new solvent recovery process eliminate use dependency nature member taskforce disposable gown naturerelate financial disclosure tnfd target material exist product develop risk management financial disclosure portfolio include remove paper leaflet move framework similar tcfd eleaflet regulation permit vaccine business water stop pvc blister pack prefille syrinx remove plastic film wrapping pallet target build capability perform ecodesign analysis achieve good water stewardship site complete detailed analysis antibiotic product reduce overall water use operation identify number project reduce environmental water neutral operation key supplier impact rd laboratory upper providence waterstresse region certify green labs consider gold zero impact api level site key supplier standard laboratory sustainability good practice world reduce overall water use operation g skcom material waste site high water stress region decrease overall water use site high biodiversity water stress region baseline achieve overall water use reduction target review target site good water steward line positive impact biodiversity site alliance water stewardship definition agricultural forestry marinederive material initially identify water basin waterstressed sustainably source deforestation free areas algeria india pakistan manufacturing progressing plan net positive biodiversity site aim water neutral manufacturing site invest individual site action plan improve facility nashik india build plant rainwater harvesting habitat protect specie improve soil water quality complete baseline biodiversity assessment commit keep api emission site commence biodiversity uplift project manufacture include contribute large rd facility complete antimicrobial resistance amr level assessment biodiversity impact entire value negative impact human health environment chain line late sbtn guidance take apply site key supplier target action address highlystresse area site supplier new sustainable source standard outline manufacture antibiotic comply amr alliance industry environmental social ethical requirement standard safe discharge meet supply chain consider sustainably partner prioritisation risk evaluation source stage address critical medicine environment premier project agricultural forestry marinederive material reach innovative medicine initiative collaboration industry target sustainably source paper palm academia regulator involve work stakeholder oil roadmap place achieve develop tool model datum characterise environmental risk engage associate supplier map apis make environmental datum apis accessible supply chain involve understand exist sustainability explore feasibility greener drug design standard identify gap establish remediation plan g skcom water value chain water footprint position pharmaceutical environment arget measure baseline environment basis reporting definition z ero impact predict effect concentration gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continued build resilience supply invest community reforestation project ghana material scope initiative help reduce create job promote gender equality support use packaging redesign portfolio consolidation provision clean water sanitation project follow type efficiency avoid altogether forestry stewardship council principle generate carbon transition synthetic alternative appropriate credit line verify carbon standard criterion environmental integrity retire support leadup un convention biological diversity carbon neutrality claim inhal product uk critical cop conference canada end invest project indonesia aim restore work partner mandatory disclosure hectare mangrove communityle project business financial institution impact project aim deliver tonne dependency nature work partner help removal credit annually cover raise business ambition nature ensure health approximately forecast residual emission healthcare sector dialogue base current carbon reduction glidepath g skcom biodiversity collaboration key ensure adequate supply highquality protect restore nature project meet rigorous standard leaf coalition lower emission accelerate forest finance invest nature protection restoration fundamental privatepublic effort protect tropical forest achieve climate nature goal positive impact test guidance voluntary carbon market integrity human health initiative work establish globallystandardised aim maximise reduction benchmark guide use carbon credit company environmental impact offset emission abate robust criterion carbon offset naturerelate financial disclosure prioritise credit highquality technically robust accredited page annual report plan project contribute land protection restoration disclose impact dependencie nature line potential deliver nature social health cobenefit emerge tnfd framework local community adaptation resilience climate change nature loss altering burden work research develop new medicine spread disease globally exacerbate exist health threat vaccine climateaggravate disease create new one put healthcare system pressure funding allocate date year billion rd increase health inequality mean health particularly investment infectious disease disproportionately impact vulnerable community key adaptation low income country focus climateaggravate disease resilience discussion global health join race resilience campaign pledge help million people resilient health impact climate change gsk biopharma company join campaign support investment partnership organisation save child microsoft gsk work support local health intervention disease surveillance commitment gsk focus nature resilience naturebase action support people water stress water resilience coalition reduce air pollution alliance clean air arget measure baseline w regulatory obligation allow exclude plastic critical product discovery development health safety gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continue energy natural gas purchase gwh electricity gwh purchase renewable electricity gwh purchase nonrenewable electricity gwh onsite renewably generate electricity gwh export electricity gwh coal gwh fossil fuel gwh renewable heat gwh purchase heating cool gwh total energy operation gwh renewable electricity carbon scope emission onsite fuel use thousand tonne coe sale force vehicle thousands tonne coe propellant emission manufacture inhaler thousand tonne coe onsite waste wastewater treatment thousand tonne coe refrigerant gas loss thousands tonne coe total scope emission thousand tonne coe electricity marketbase emission thousand tonne coe purchase heating cool thousand tonne coe total scope marketbase emission thousand tonne coe total scope locationbase emission thousand tonne coe total scope marketbase emission thousand tonne coe pr fermentationbiogenic release thousands tonne coe carbon scope emission purchase good service thousand tonne coe capital good thousand tonne coe fuel energyrelate activity thousand tonne coe transportation distribution upstream thousand tonne coe waste generate operation thousand tonne coe business travel thousands tonne coe employee commute thousand tonne coe lease asset upstream thousand tonne coe transportation distribution downstream thousand tonne coe processing sell product thousand tonne coe pr metric contribute esg performance rating metric datum externally assure cope emission datum assure metric tonne base data available gskcom ther propellant emission datum collect internal system scope emission report unable split previous consumer healthcare business datum accurate picture scope emission late year gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continue use sell product thousand tonne coe emission use propellantbase inhaler patient thousands tonne coe end life thousand tonne coe lease asset downstream thousands tonne coe franchise thousand tonne coe investment thousand tonne coe total scope emission thousand tonne coe ozonedeplete substance odp inventory cfc hcfc equipment kg cfce odp calculate release cfce kg cfce water use municipal million ground water million tanker million total water use million recycle source million water use high water risk site million water discharge wastewater municipal sewer million wastewater surface water million wastewater land million wastewater million total wastewater discharge million gsk site supplier location gsk compliant amr alliance pr wastewater api limit pr metric contribute esg performance rating metric datum externally assure ther propellant emission datum collect internal system scope emission report unable split previous consumer healthcare business datum accurate picture scope emission late year w ater use datum assure base datum available gskcom gsk esg performance report march approach access global health environment dei ethical standard product governance appendix environment continue waste material total waste recover circular route thousand tonne total waste dispose noncircular route thousand tonne total waste material generate thousand tonne pr circular waste total hazardous waste recover circular route thousand tonne total hazardous waste dispose noncircular route thousand tonne total hazardous waste thousand tonne total nonhazardous waste recover circular route thousand tonne total nonhazardous waste dispose noncircular route thousand tonne total nonhazardous waste thousand tonne total hazardous waste incinerate thousand tonne total nonhazardous waste incinerate thousand tonne total waste incinerate thousand tonne total hazardous waste landfill thousand tonne total nonhazardous waste landfill thousand tonne total waste landfill thousand tonne sustainable source number highrisk material implement sustainable source roadmap pr compliance remediation environmental fine remediation spend pr metric contribute esg performance rating metric datum externally assure datum record breakdown datum unable report certain metric year waste metric originally select information subject independent assurance deloitte report deloitte matter section independent assurance report page course assurance engagement deloitte unable obtain evidence need support conclusion complexity waste data significant remediation require measurement report waste metric gsk take additional support party complete remediation addition request deloitte remove waste metric scope assurance engagement datum include previous consumer healthcare business gsk esg performance report march approach access global health environment dei ethical standard product governance appendix diversity equity inclusion want ensure people thrive foster diversity clinical trial support diverse community inclusive business central purpose vpandabove role hold ethnically diverse leader vp phase iii trial include woman globally level demographic plan commitment create diverse equitable inclusive workplace enhance ethnically diverse leader role recruitment diverse patient population clinical trial vp increase percentage support diverse community black african american hispanic latinx vpand leader year year assess performance ethnically diverse leader role phase iii trial initiate proactive vp uk increase percentage plan place design enrol appropriately diverse trial black vpandabove leader year year participant consistent disease epidemiology improve yearonyear spend certify usbased diverse performance aspiration fair own supplier equitable opportunity woman hold vpandabove role globally end diversity equity inclusion dei central purpose want inclusive workplace gsk people reflect get ahead disease inclusive community operate leadership reflect diverse business business inclusively make gsk people help company perform well successful make people potential bring well insight well quality decision make increase positive impact want well health outcome crucially help understand diverse patient sure clinical trial reflect work stem education equitable population affect disease increase number underrepresented people stem career focus plan increase focus uk help ensure health innovator future diverse building inclusive business disease disproportionately impact specific patient group end gsk phase iii trial diversity safety efficacy medicine vaccine differ plan place enrol group affect disease base genetic environmental factor study base epidemiology datum example appropriate representation clinical research critical hepatitis b trial disease disproportionately affect people advance understand new medicine vaccine african asian descent participant asian ensure big impact patient origin actively work improve representation commit improve diversity clinical trial enrolment participant african descent disease insight set diversity enrolment goal g skcom approach clinical trial know barrier negatively impact clinical trial turnout certain patient population access transportation strengthen supply chain support language difference lack trust awareness diverseowne supplier work patient advocacy group academic organisation tackle supplier diversity programme establish expansion plan develop uk collaborate regulator patient programme seek provide opportunity biopharma company wide healthcare ecosystem represent group include woman ethnic minority member meaningful progress diverse lgbt community people disability military participation clinical trial achieve share goal well veteran small business highunemployment health outcome lowincome communities gsk esg performance report march approach access global health environment dei ethical standard product governance appendix diversity equity inclusion continue engage mentor small diverseowne business significantly exceed combination supply chain help identify potential area spend increase select supplier marketing sale growth target increase spend annually technology identification new global diverse certify usbased diverseowned supplier supplier strong multiyear strategy engagement key advocacy group nurture people code require people commit inclusive ethnically diverse leader vp aware impact annual mandatory level reach aspirational target training create inclusive workplace set increase percentage black african american standard expect hispanic latinx people role year year uk ethnically diverse leader vp g skcom code continue progress aspirational building diverse team fair equitable target reach black representation vp remain flat focus effort achieve opportunity aspiration yearonyear growth commit equality representation build representative workforce workforce reflect community work hire representative pool job applicant engage gsk leadership reflect workforce historically black college university hispanic commit increase representation woman serve institution encourage application graduate ethnically diverse people senior role ensure position target recruitment campaign reach recruitment selection process fair equitable represent group manager commit build diverse inclusive g skcom gender pay gap report team expect diverse shortlist gender ethnicity vacancy senior grade work foster inclusion workplace recruitment agency internal employee representation group erg specialist organisation continue gain insight working create inclusive workplace accessible support drive progress hire manager require culture empathy acceptance complete inclusive interview training start embrace difference identity selection process work build future pipeline member uk government disability confident accelerate difference programme support development scheme launch threeyear plan increase woman ethnically diverse leader individual group disability confidence gsk active coach accelerate readiness future role member valuable pledge group global woman hold vpandabove role globally company commit place disability inclusion compare bring close leadership agenda deliver scheme objective aspirational target woman employee longterm measurable disability confidence plan management role include educate people issue remain committed improve application fair look well support people equitable pay practice ensure equal opportunity equal different life stage make sure offering pay equal work conduct countrybase review fair inclusive introduce new global minimum ensure market clear guidance tool support standard week parental leave primary secondary ensure pay equity unexplainable difference detect carer form family new global minimum standard address compensation process publish care family member end life health sixth uk gender pay gap report gender pay gap emergency insure benefit include sex partner permanent ukbased gsk employee mean possible new financial wellbeing service mental compare national average health training available publish uk ethnicity pay gap report year recognise gold employer stonewall approach gender pay gap ethnicity pay gap global employer index allyship programme receive permanent ukbased gsk employee mean time award recognise tangible impact campaign national average comparator give commitment live lgbt employee programme launch end diversity share uk ethnicity pay gap datum base help people effective ally support approach gender pay gap recognising adjustment colleague feel welcome value include achieve calculation methodology require future human right campaign foundation good place work lgbt equality standard country meet criterion datum confidentiality anonymity disclose race ethnicity people level set aspirational target currently uk meet criterion gsk esg performance report march approach access global health environment dei ethical standard product governance appendix diversity equity inclusion continue support diverse scientist future support community world global reach student nationwide health partnership local community investment response commit invest million year humanitarian emergency stem education programme increase number woman black latinx student underrepresented group philadelphia enter stem career local nonprofit receive grant far gsk stem equity grant reach gsk science summer initiative offer free handson student stem learn student traditionally underrepresented group stem career underresource community gender diversity woman employee svpvp level pr director level manager level total woman management woman board share woman stemrelate position total stem position woman management position revenuegenerate function svpvp director manager employee ethnic diversity american indian alaska native asian black african pr american hispanic latinx pr native hawaiian pacific islander race ethnically pr diverse total white total uk ethnic diversity asian black pr mix ethnically pr diverse total white total pr metric contribute esg performance rating metric datum externally assure w ith exception woman board share woman stemrelate position woman management position revenuegenerate function datum display reflect gsk employee include align consumer healthcare business december report year datum represents actively respond identify gender category actively respond indicate prefer datum represent respond identify race ethnicity category employee actively respond identify race ethnicity category indicate prefer uk actively respond indicate prefer round sum datum marginally different total nsufficient datum report few employee gsk esg performance report march approach access global health environment dei ethical standard product governance appendix ethical standard culture guide people right thing speak concern important people live expect supplier employee complementary employee believe direct highrisk supplier worker complete speak achieve minimum mandatory training thing feel right ecovadis score commitment promote ethical behaviour business support percentage employee believe employee right thing work supplier speak thing not feel right general share standard operate responsible way industry benchmark number employee leave gsk employment assess performance misconduct month versus threeyear employee complementary worker complete rolling average gsk mandatory training direct highrisk supplier achieve gsk minimum ecovadi score improvement plan place support gsk people right thing expect work behalf report investigate concern conduct right way builds trust inside outside gsk raise concern speak protect business help create workplace integrity line confidentially anonymously fear thrive thing important retaliation concern seriously review launch new code conduct reflect report need investigate formally purpose unite science technology talent ahead investigation employee breach policy disease new code set commitment action company deliver purpose year update report breakdown ambition code support additional global type policy violation provide granularity case class policy standard locate new code hub broad distribution policy area additionally people require complete category historically report see overall accompany global mandatory learn curriculum living decrease disciplinary case attribute revision code comprise module code create procedure discipline late completion inclusive workplace protect gsk protect gsk focus mandatory training report employee conduct key risk area antibribery corruption abac category majority environment health safety ehs cyber security privacy report human safety sustainability category increase write information relate product speak warning relate compliance company covid employee complementary worker vaccination mandate safety testing requirement ensure complete training year end health safety wellbee workforce certain highrisk role geographic region continue embed great focus use risk complete additional abac training help identify analytic monitoring align increase level business mitigate potential abac risk especially thirdparty activity enhance risk identification target intervention relationship recognise report manage additionally focus closure case result conflict interest employee decrease open case year end prior year complementary worker complete training correlation rise number employee dismiss year end agree leave company voluntarily result approach manage abac risk risk relate misconduct ethical standard form embed risk management framework describe detail annual report page g skcom antibribery corruption policy code general industry benchmark accord research kornferry gsk esg performance report march approach access global health environment dei ethical standard product governance appendix ethical standard continue uphold commitment human right commit respecting internationally recognise committed application fair equitable pay human right business continue practice include ensure employee globally progress integrate salient human right access receive pay competitive local market sufficient healthcare research practice patient safety ehs privacy support sustainable standard living complete operation conduct business global living wage review partnership fair wage foundation assess pay employee signatorie un global compact human people country difference right position statement lay commitment un detect few case country necessary guiding principle business human right adjustment end quarter year establish human right steering group factoring living wage datum standard formal reporting mechanism board compensation process ensure continue offer corporate responsibility committee steering group fair wage build annual living wage review comprise senior representative key business function standard cycle accountable ensure respect human right information uphold commitment business area steering group facilitate human right refer modern slavery act statement attend external human right expert g skcom position human right modern slavery act statement develop guidance enhance supplier visit help employee well understand labour human right noncompliance support guidance develop deliver labour right training ehs procurement employee well equip spot human right issue visit supplier work party supplier party include agent additional support ehs risk large supplier distributor affiliate company equity stake include supply globally medically critical product help research develop manufacture distribute critical rd large spend help medicine vaccine product patient need supplier improve safety management system build overall party act direct impact ehs capability focus active pharmaceutical ingredient important manage relationship include manufacturer contract manufacturing supplier set ehs way choose contract monitor requirement review performance internal ehs governance oversight expect party meet abac labour right standard relevant comply standard visit site person virtually help supplier well quality health safety environment annual understand control risk relaxation travel report page restriction allow increase inperson visit identify reduce risk enable conduct physical visit update thirdparty risk management programme priority supplier year complete warehouse safety evaluate mitigate risk introduce party survey priority supplier contract manufacturing engage gsk provide good service supplier large warehouse hold stock year highrisk party determine location survey generate corrective preventative action plan highrisk market size spend perform expect complete assessment risk area assessment conduct supplier audits compare present risk area party follow industry standard pharmaceutical supply chain good service provider distributor initiative guideline corrective preventative action wholesaler contract manufacturer supplier track completion train direct material supplier use tool assess supplier employee ehs esg fundamental supplier manage risk include ecovadis desktop assessment revise ehs contractual obligation track management action completion help supplier improve ecovadis score annual report g skcom position work party g sk maintain list globally medically critical product drug product approve treat lifethreatening disease medical condition adequately available alternative gsk provider ur eh priority supplier api supplier medically rd revenuecritical gsk high spend supplier supplier employee train include datum previous consumer healthcare business gsk esg performance report march approach access global health environment dei ethical standard product governance appendix ethical standard continue datum engagement exercise high standard integrity deal datum responsibly personal information employee patient clinical research privacy ethical use datum global participant healthcare provider stakeholder mandatory learn curriculum live code people datum security privacy landscape rapidly change complete mean understand gsk threat cyber security constantly proliferate responsible handling personal information right way introduction privacy regulation national statelevel ensure key privacy personnel certification authority require continual assessment review sufficient training experience carry role effectively privacy framework control response create invest artificial intelligence machine learn new digital privacy information security team legal capability example help analyse patient genetic datum compliance streamline support provide expertise mindful artificial intelligence machine learn gsk digital datum strategy global team raise ethical issue subject evolve decision partner business assess impact change policymaker well promote trust system global local privacy regulation mitigate related risk avoid unintended outcome harmful impact annual report page rd oversight board new advisory panel oversee control manage use reuse datum respond bioethical question research activity make sure follow regulation meet ethical obligation political engagement heavily regulate industry business model political engagement commit ensure market influence legislation regulation adhere high ethical standard legislative major multinational company seek contribute requirement corporate political contribution public policy debate especially relation life sciences sponsor party political meeting healthcare stakeholder non world governmental organisation scientist healthcare professional g skcom position political advocacy political advocacy disclosure patient industry group frequently invite government view development new policy ethical conduct employee concern raise include current year prior year open case employee discipline policy violation breakdown type policy violation employee conduct sale marketing product quality safeguard people information asset employee relation hr policy rd medical practice antibribery corruption computer databreach security ehs sustainability pr metric contribute esg performance rating metric datum externally assure n update report methodology breakdown type policy violation provide granularity case class broad distribution policy area category historically report enable comparison prior year datum restate new reporting methodology n change process circumstance trigger discipline late completion mandatory training report employee conduct result see few disciplinary case compare prior year majority eh sustainability category increase write warning relate compliance company covid vaccination mandate safety testing requirement ensure health safety wellbee workforce p olicy violation class type fit class category specify gsk esg performance report march approach access global health environment dei ethical standard product governance appendix ethical standard continue employee dismiss agree leave company voluntarily result misconduct pr document warning open case await investigation disciplinary decision year end mandatory training employee complementary worker complete gsk mandatory training pr employee complete gsk mandatory training code living value expectation work gsk complementary worker complete gsk mandatory training code living value expectation work gsk employee complete gsk mandatory training abac complementary worker complete gsk mandatory training abac report concern employee believe speak thing not feel right pr supplier direct highrisk supplier achieve gsk minimum ecovadi score pr improvement plan place supplier spend region asiapacific europe middle east africa latin america north america political engagement spend federal lobbying activity trade association membership spend corporate political contribution political action committee contribution employee state federal candidate european political engagement trade association membership spend corporate political contribution cost represent interest eu institution pr metric contribute esg performance rating metric datum externally assure n continue embed great focus use risk analytic monitoring align increase level business activity enhance risk identification target intervention additionally focus closure case result decrease open case year end compare prior year correlation rise number employee dismiss agree leave company voluntarily result misconduct hese figure base active employee complementary worker year end datum split employee complementary worker disclose prior esg report round near number include datum previous consumer healthcare business attrition year restate completion rate provide comparable metric update way report completion mandatory training combine metric employee complementary worker mandatory training single metric rounded near number irect highrisk supplier identify yearly basis combination spend category highrisk country direct procurement involve purchase material directly associate production good include datum previous consumer healthcare business g sk corporate political contribution sponsor political meeting world include late available figure previous year figure report year publish march publication document gsk esg performance report march approach access global health environment dei ethical standard product governance appendix product governance ensure quality safety reliable supply product critical protect patient deliver health impact regulatory inspection quality audits clinical trial protocol manufacturing site local supplier summary register operating company summary result commitment commit maintain robust quality safety process number fda warning letter datum new technology responsibly total number class iii external product recall market assess performance register disclose human subject research gsk average number critical major finding product specifically register protocol summary study fdamhraema regulator initiated disclose result summary study percentage inspection regulator critical result finding official action indicate quality safety product exceptionally important help deliver reliable supply highquality product system place gsk ensure meet support valuesdriven culture issue respond high standard set company swiftly transparently expect externally focus quality management gsk quality management system detail specific regulatory inspection manufacture framework describe comply regulatory site local operating company compare requirement standard market remain prepared inspection regulator receive address global local regulation manufacturing warning letter united states food drug distribution process base principle define administration fda critical finding medicine international council harmonisation technical healthcare product regulatory agency mhra european requirements pharmaceutical human use medicine agency ema regulator receive critical finding chinese regulator continue responsibility quality assurance manage gsk learn respond inspection finding take quality organisation extensive global network quality necessary action address compliance professional business unit sitelevel senior management class product recall few class ii iii recall compare quality management system detail patient safety hesitate voluntarily recall product protect patient quality process training require gsk people include induction hygiene safety technical skill train work supplier quality good distribution manufacturing practice training employee carry specific qualitycritical sensitive activity expect contract manufacturer supplier comply subject additional check necessary gsk standard regularly conduct audits verify conduct quality audits supplier inspection recall audit increase focus active pharmaceutical ingredient supplier subject regulatory inspection market supply comprehensive quality oversight model align product provide independent assurance high quality management system use riskbased standard quality place development manufacturing approach assess qualify manage monitor thirdparty distribution require maintain licence operate supplier ongoing basis drive continuous performance w e consider observation fda major c ritical find inspection chinese regulator thirdparty manufacturing facility gsk c lass recall trigger reasonable probability use exposure violative product cause adverse health consequence death class ii recall address use exposure violative product cause temporary medically reversible adverse health consequence probability adverse health consequence remote class iii recall relate use exposure violative product likely cause adverse health consequence gsk esg performance report march approach access global health environment dei ethical standard product governance appendix product governance continue maintain pharmacovigilance pharmacovigilance aim protect use medicine vigilance falsify medicine vaccine vaccine support public health programme reliable robust approach handle falsify product comprehensive information overall benefitrisk balance incident ensure case confirm counterfeit product product establish rigorous worldwide report relevant regulatory authority system monitor review safety product actively participate legal proceeding illegal clinical development regulatory approval actor provide regular training custom local authority maintain high standard safety medical governance monitor online marketplace social medium request ensure partner meet expectation takedown site illicitly sell prescriptiononly medicine review thirdparty safety system monitor contractual g skcom position falsify substandard healthcare product obligation foster collaboration life cycle relationship g skcom position pharmacovigilance commit transparency commitment transparency clinical trial datum reflect commitment protocol wish help advance scientific understanding enable summary summary result available scientific community learn research undertake setup gsk trial register list allow acknowledge great contribution study datum share wwwvivliorg people clinical research wwwclinicalstudydatarequestcom regulatory inspection audits audits party quality process total regulatory inspection health authority pr inspection regulator critical finding official action indicate pr total regulatory inspection fdamhraema regulator pr number criticalmajor finding fdamhraema regulator pr total fda regulatory inspection pr number fda observation pr number fda warning letter pr product recall total number class external product recall pr total number class ii external product recall pr total number class iii external product recall pr total product recall pr metric contribute esg performance rating metric datum externally assure include datum previous consumer healthcare business audit conduct jointly consumer healthcare pharmaceutical datum point adjust additional inspection identify inspection remove retrospectively identify scope reporting criterion gsk esg performance report march approach access global health environment dei ethical standard product governance appendix product governance continue fda product recall business class pharmaceutical business class product recall pr class ii product recall pr class iii product recall vaccine business class product recall pr class ii product recall pr class iii product recall clinical trial management pharmacovigiliance transparency clinical trial audits trial conduct party behalf number fda sponsor inspection relate clinical trial management pharmacovigilance result voluntary action indicate vai number fda sponsor inspection relate clinical trial management pharmacovigilance result official action indicate oai clinical study reportsstudy report synopsis gsk study register trial anonymise datum available meeting define eligibility criterion research team approve access gsk trial datum publicly available trial protocol summary register pr publicly available trial result summary disclose pr pr metric contribute esg performance rating metric datum externally assure datum include recall market initiate voluntarily gsk request fda mandate fda statutory authority represent total pharmaceutical product produce market include datum previous consumer healthcare business make approximately figure hese figure cumulative gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix materiality assessment gsk conduct materiality assessment process process issue identify material engagement analysis identifie prioritise business external stakeholder illustrate esg issue pose significant risk opportunity matrix issue identify process help business gsk significant impact confirm esg focus area access global health health materiality assessment inform strategic decision security environment diversity equity inclusion ethical making help prioritise issue cover public reporting standard product governance year datamarans datum analytic platform read materiality methodology process conduct assessment software monitor external esg key observation materiality overview gskcom risk assess coverage issue peer annual g skcom materiality assessment sustainability report regulatory legislative document media social medium conduct stakeholder engagement internal external interview analysis investor rating ranking report medium high importance business gsk esg performance report march sredlohekat lanretxe ot ecnatropmi materiality matrix high product quality privacy patient safety datum security supply chain management product innovation global health security labour right healthcare access affordability ethical business conduct employee health safety wellbee clinical trial conduct climate change talent attraction retention nature environmental protection waste hazardous material management diversity equity water wastewater management inclusion key access environment ethical standard global health diversity equity product governance health security inclusion people cultureour approach access global health environment dei ethical standard product governance appendix appendix continue people disclosure positive experience work critical attract retain keep people safe motivate good people want workplace embrace care deeply health safety employee everyone unique difference encourage growth complementary worker work visit development safe environment people perform site commitment go home safely good work information life save rule embed company people heart success rule simple standardise easy remember detail focus diversity equity inclusion responsibility safety leader individual review level organisation risk assessment key environment health safety ehs freedom association control framework govern approach identify respectful right colleague join control hazard conduct health safety training independent trade union right collectively bargain people specific work office freedom association global employee cover lab manufacturing site commercial recent key collective bargaining arrangement declare initiative include safety leadership warehouse safety member union gsk invest heavily driver safety formal information consultation arrangement actively g skcom environment health safety policy involve provide additional employee voice high proportion colleague hire total number new hire open position fill internal candidate employee turnover overall turnover turnover voluntary leaver permanent leaver male permanent leaver female workforce breakdown age permanent employee year old year old year old engagement employee survey engagement score employee survey response rate talent leadership development number graduate recruit future leader programme number postgraduate recruit esprit programme number apprentice recruit metric datum externally assure n certain market datum unavailable privacy reason c alculate number permanent employee voluntarily leave gsk divide average permanent headcount c alculated number permanent employee leave gsk reason period male female divide total number permanent leaver leave reason period engagement datum derive gsk annual survey total employee base invite participate engagement datum derive q pulse survey statisticallyrelevant randomise sample population represent average gsk employee invite participate employee survey engagement score report consistent methodology type survey derive comparable engagement score employee survey response rate report methodology administer pulse survey subsequent response rate comparable gsk annual survey include response align previous consumer healthcare business gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue health safety number fatality employee complementary worker gsk direct supervision number fatality contractor gsk direct supervision reportable injury lose time reportable illness lose time lose time reportable injury rate hour work lose time reportable illness rate hour work reportable injury lose time reportable illness lose time reportable injury rate hour work reportable illness rate hour work reportable injury illness rate hour work hour work metric datum externally assure total equal exact sum constituent round gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue gri guideline sasb index gri indicator description find information general disclosure organisational detail legal gsk plc ownership annual report share capital share price hq address brentford middlesex tw gs uk operation annual report business model entity include organisation sustainability reporting gsk plc reporting period frequency contact point sustainability financial annual reporting period january december report publication march contact csrcontactgskcom restatement information demerger comparative result restate reflect demerger consumer healthcare business specify restatement information detail relevant specific data point report external assurance independent limited assurance statement page activity value chain business relationship sector healthcare pharmaceutical annual report business model change compare previous reporting period follow demerger consumer healthcare business form haleon july fully focus biopharma company employee fulltime employee fte december annual report employee gender change compare previous reporting period follow demerger consumer healthcare business form haleon july fullyfocused biopharma company worker employee report governance structure composition annual report board gsk leadership team annual report corporate governance architecture annual report nomination corporate governance nomination selection high governance body committee report chair high governance body gsk independent nonexecutive chair board role high governance body oversee annual report corporate responsibility committee report management impact delegation responsibility manage impact annual report corporate responsibility committee report role high governance body sustainability report esg performance report review gsk leadership team board conflict interest annual report director conflict interest communication critical concern annual report board committee report collective knowledge high governance body annual report board evaluation performance high governance body annual report board performance remuneration policy annual report annual report remuneration process determine remuneration annual report annual report remuneration annual total compensation ratio annual report annual report remuneration statement sustainable development strategy annual report ceo statement policy commitment policy position include human right policy approve gsk leadership team level apply grouplevel embed policy commitment corporate responsibility committee process remediate negative impact annual report principal risk uncertaintie ethical standard ethic compliance grievance mechanism gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue gri indicator description find information mechanism seek advice raise concern ethical standard grievance mechanism compliance law regulation annual report audit risk committee report membership association trade association memberships approach stakeholder engagement materiality assessment collective bargaining agreement people disclosure page position human right process determine material topic materiality assessment list material topic materiality assessment management material topic materiality assessment economic performance direct economic value generate distribute annual report financial statement financial implication risk opportunity annual report risk management climate change annual report tcfd define benefit plan obligation retirement plan annual report annual report remuneration financial assistance receive government annual report financial statement annual report share capital share price anticorruption operation assess risk relate corruption annual report risk management communication training anticorruption policy ethical standard page procedure confirm incident corruption action take ethical standard page tax approach tax gsk tax strategy tax governance control risk management gsk tax strategy stakeholder engagement management concern gsk tax strategy relate tax countrybycountry reporting gsk tax strategy energy energy consumption organisation environment page environment basis report energy consumption outside organisation environment page environment basis report energy intensity annual report risk management environment basis reporting reduction energy consumption environment page environment basis reporting reduction energy requirement product service environment page environment basis report water interaction water share resource environment page management water dischargerelate impact environment basis report water withdrawal environment page environment basis report water discharge environment page environment basis report water consumption environment page environment basis reporting gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue gri indicator description find information emission direct scope ghg emission environment page environment basis report energy indirect scope ghg emission environment page environment basis report indirect scope ghg emission environment page environment basis report ghg emission intensity annual report tcfd environment basis reporting reduction ghg emission environment page environment basis reporting emission ozonedeplete substance od environment page environment basis report nitrogen oxide nox sulfur oxide sox significant report air emission waste waste generation significant wasterelate impact environment page management significant wasterelate impact environment page environment basis reporting waste generate environment page environment basis reporting waste divert disposal environment page environment basis report waste direct disposal environment page supplier environmental assessment new supplier screen environmental ethical standard page criterion negative environmental impact supply chain ethical standard page action take employment new employee hire employee turnover people disclosure page benefit provide fulltime employee life gsk provide temporary parttime employee parental leave report occupational health safety occupational health safety management system gsk ehs policy hazard identification risk assessment incident gsk ehs policy investigation occupational health service gsk ehs policy worker participation consultation communication gsk ehs policy occupational health safety worker train occupational health safety gsk ehs policy promotion worker health gsk ehs policy prevention mitigation occupational health safety gsk eh policy impact directly link business relationship worker cover occupational health safety gsk ehs policy management system workrelate injury people disclosure page gsk ehs policy workrelate ill health gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue gri indicator description find information diversity equal opportunity diversity governance body employee diversity equity inclusion page people disclosure page ratio basic salary remuneration woman man gender pay gap report diversity equity inclusion human right labour right operation supplier right freedom gsk position human right association collective bargaining risk operation supplier significant risk incident gsk position human right child labour modern slavery act statement operation supplier significant risk incident gsk position human right force compulsory labour modern slavery act statement new supplier screen social criterion ethical standard page negative social impact supply chain action ethical standard page take public policy political contribution political advocacy disclosure customer health safety assessment health safety impact product product governance page service category incident noncompliance concern health product governance page safety impact product service marketing labelling requirement product service information code practice label incident noncompliance concern product service product governance page information labelling incident noncompliance concern marketing product governance page communication sasb indicator description find information drug safety hcbpa list product list food drug administration available fda fda medwatch safety alert human medical product database hcbpa number fatality associate product report available fda fda adverse event report system hcbpa number fda recall issue total unit recall product governance page hcbpa total product accept takeback reuse report disposal hcbpa number fda enforcement action take response product governance page violation current good manufacturing practice cgmp type counterfeit drug hcbpa description method technology maintain product governance page traceability product supply chain position falsify prevent counterfeit substandard healthcare product hcbpa discussion process alert customer business product governance page partner potential know risk associate position falsify counterfeit product substandard healthcare product hcbpa number action lead raid seizure arrest andor report file criminal charge relate counterfeit product gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue sasb indicator description find information ethical marketing hcbpa total monetary loss result legal report proceeding associate false marketing claim hcbpa description code ethic govern promotion code practice promotional nonpromotional external offlabel use product interaction employee recruitment development retention hcbpa discussion talent recruitment retention effort approach page scientist research development personnel hcbpa voluntary involuntary turnover rate people disclosure page executivessenior manager b midlevel manager c professional supply chain management hcbpa percentage entitys facility tier supplier gsk member rx facility participate rx international conduct audits pharmaceutical supply chain consortium audit programme party equivalent thirdparty audit programme integrity product governance page supply chain ingredient business ethic hcbpa total monetary loss result legal report proceeding associate corruption bribery hcbpa description code ethic govern interaction engagement healthcare professional healthcare professional activity metric hcbpa number patient treat access page patient reach access strategy hcbpb number drug portfolio research annual report pipeline product competition development phase gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue list product list prequalifie medicinal product vaccine prequalification medicine programme pqp type form presentation date prequalification vaccine engerix hepatitis b liquid ready use vial dose thursday january engerix hepatitis b liquid ready use vial dose thursday january engerix hepatitis b liquid ready use vial dose thursday january priorix measle mump rubella lyophilise active component reconstitute friday march excipient diluent use vial dose rotarix rotavirus liquid ready use plastic tube dose thursday march rotarix rotavirus liquid ready use applicator dose thursday march cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july cervarix human papillomavirus bivalent liquid ready use vial dose wednesday july polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial dose thursday october polio sabin polio vaccine oral opv bivalent type liquid ready use vial dose thursday october polio sabin polio vaccine oral opv bivalent type liquid ready use vial dose thursday october synflorix pneumococcal conjugate liquid ready use vial dose friday october synflorix pneumococcal conjugate liquid ready use vial dose friday march polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose tuesday october polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose tuesday october polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose wednesday polio sabin mono oral polio vaccine oral opv monovalent type liquid ready use vial dose wednesday priorix measle mump rubella lyophilise active component reconstitute wednesday december excipient diluent use vial dose hepatitis human diploid cell inactivate adult liquid ready use vial havrix adult friday july dose havrix junior hepatitis human diploid cell inactivate paediatric liquid ready use vial friday july dose boostrix diphtheriatetanuspertussis acellular liquid ready use vial dose tuesday july menveo meningococcal acyw conjugate vaccine lyophilise active component wednesday july reconstitute liquid active component use vial set dose synflorix pneumococcal conjugate liquid ready use vial dose monday october rotarix rotavirus liquid ready use plastic tube dose thursday february mosquirix plasmodium falciparum malaria hepatitis b recombinant adjuvante friday july liquid active component mixed second component use vial set dose pharmaceutical abacavir sulfate hiv viiv healthcare ha march abacavir sulfate hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha zidovudine hiv viiv healthcare ha lamivudinezidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march dolutegravir sodium hiv viiv healthcare ha october abacavir sulfatelamivudine hiv viiv healthcare ha june dolutegravir sodium hiv viiv healthcare ha july zanamivir influenza gsk september gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue esg report criterion state datum reflect report period january december kpi definition method access total community donation gsk globally donation include voluntary charitable purpose investment charitable purpose include cash product donation value gbp yearend exchange rate inkind donation value time donate product donation value global average cost good report philadelphia stem equity collective yearend result management cost associate charitable programme inkind donation value value cost item gsk current external purchase price previous year datum include comparison restate inflation exchange rate change methodology follow bsi lbg framework corporate community investment value gsk medicine value medicine vaccine provide gsk viiv patient assistance program foundation administer vaccine provide gsk viiv healthcare patient patient assistance program patient puerto rico patient assistance program foundation provide virgin islands assistance program medication charge eligible individual capture patient assistance program order gsk viiv cog million usd patient receive medication healthcare product internal ordering database datum patient assistance program meet capture accord wholesale acquisition cost medicine eligibility requirement requirement vaccine code free good charitable order include insurance status financial component convert cost good sell reporting purpose base federal poverty level patient participation vary annually base current program eligibility resident puerto rico virgin criteria overall healthcare environmental factor product include island treat uslicensed program healthcare provider dose rotarix number dose rotarix synflorix calculate number dose supply use number gsk synflorix cervarix cervarix vaccine supply gavi dose ship gavi support country vaccine supply vaccine alliance gsk gavi supplier gavis inception gavi millions dose opv number dose opv vaccine calculate number dose supply use number gsk vaccine supply supply unicef dose ship country procure unicef unicef millions dose mosquirix number dose mosquirix rtss calculate number dose supply use number gsk rtssa e e vaccine donate malaria vaccine dose procure unicef mvip procurement agent ship vaccine supply implementation programme mvip mvip countries ghana kenya malawi mvip gsk supply mosquirix rtssa e millions malaria vaccine begin mvip albendazole tablet number albendazole tablet donate albendazole tablet shipment send gsk manufacturing facility donate help world health organization support endemic country shipment enter realtime database eliminate lymphatic endemic country effort eliminate lymphatic donate medicine neglect tropical disease albendazole tablet filariasis million filariasis donation figure lymphatic filariasis aggregate report annually datum pull system albendazole tablet number albendazole tablet donate albendazole tablet shipment send gsk manufacturing facility donate help treat world health organization support endemic country shipment enter realtime database intestinal worms endemic country effort treat soiltransmitted donate medicine neglect tropical disease albendazole tablet million helminthiasis intestinal worm schoolage donation figure soiltransmitte helminthiasis control aggregated child report annually datum pull system people access total number people live hiv chronic ongoing treatment capture cumulative number generic dolutegravir currently access generic dolutegravirbase people access dolutegravir annual datum avoid product product viiv healthcare voluntary duplication indicator represent total number people voluntary licensing license agreement medicine patent live hiv access treatment time measurement agreement pool directly aurobindo pharma lifelong treatment number incorporate people receive ongoing treatment multiple year number calculate add total number pack generic dolutegravirbase product sell previous quarter divide obtain average monthly sale estimate number people treatment pack convert pack equivalent ie monthly equivalent daily treatment datum provide medicine patent pool aurobindo viiv dolutegravir patent sublicense gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue kpi definition method access estimate child estimate number child calculate estimate number child reach use number reach synflorix receive synflorix vaccine prevention gsk dose ship gavi support country divide gavi pneumococcal infection gavi number dose need complete schedule gavi estimate vaccine alliance vaccine wastage rate factor synflorix schedule child receive synflorix dose gavi estimate wastage year age detailedproductprofilesxlsx livecom estimate child estimate number child calculate estimate number child reach use number reach rotarix receive rotarix vaccine prevention gsk dose ship gavi support country divide gavi rotavirus gavi vaccine alliance number dose need complete schedule gavi estimate child receive rotarix year vaccine wastage rate factor rotarix schedule dose age gavi estimate wastage detailedproductprofilesxlsx livecom estimate girl estimate number girl calculate estimate number girl reach use number gsk reach cervarix receive cervarix vaccine prevention dose ship gavi support country divide number gavi cervical cancer gavi vaccine dose need complete schedule gavi estimate vaccine alliance wastage rate factor cervarix schedule dose gavi estimate wastage detailedproductprofilesxlsx livecom estimate people estimate number people calculate estimate number people reach use number reach oral receive opv vaccine polio procured bivalent opv bopv monovalent opv mopv dose ship polio vaccine opv unicef unicef divide number dose need complete unicef schedule estimate vaccine wastage rate factor outbreak situation gsk opv volume dose usually give child primary schedule dose child receive dose subsequent outbreak campaign use dose calculation order conservative estimate wastage give supply dose vial vial mainly campaign vial discard vial open end session indicative vaccine wastage rate revisingwastageconceptnotepdf whoint estimate people estimate number child calculate estimate number child reach use number reach receive mosquirix rtssa e vaccine gsk dose ship mvip country ghana kenya malawi divide mosquirix rtssas malaria vaccine implementation number dose need complete schedule dose e mvip programme mvip estimate vaccine wastage rate dose vial routine immunisation factor indicative vaccine wastage rate revisingwastageconceptnotepdf whoint people reach total number unique individual gsk viiv patient assistance program foundation administer patient receive gsk viiv healthcare product patient assistance program patient puerto rico assistance program patient assistance program virgin islands patient receive medication patient assistance program provide report year end patient assistance program meet eligibility enable consolidate number unique patient receive requirement requirement include gsk viiv healthcare product year insurance status financial component base patient participation vary annually base current program eligibility federal poverty level resident criterion overall healthcare environmental condition product include puerto rico virgin islands program treat uslicensed healthcare provider gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue kpi definition method global health health security number asset number asset progress pipeline progression define movement global health asset progress global health pipeline address priority phase gsk recognise progression global health disease gsk global health hub follow category pipeline address tre canto spain focus senior leadership endorsement business plan progression priority disease therapeutic gsk vaccines institute clinical trial start subject visitdose global health gvgh sienna focus business developmentinlicense preventative treatment regulatory milestone ie submission approval launch priority disease define disease pathogen prioritize rd public health emergency context distinguish disease degree pose great public health risk epidemic potential andor insufficient countermeasure gsk use follow list priority pathogen list emergency disease list blueprint prioritize disease list essential medicine list un sustainable development goal review update list needs arise methodology change environment list environment report criterion basis reporting include definition methodology diversity equity inclusion gender diversity percentage woman break datum cover total number employee identify woman svpvp director manager employee hr system include active fulltimeparttime regulartemporary total percentage woman employee nonactive ie maternity leave paternity leave management management class adoption leave etc exclude agency temporary worker contingent employee grade band include worker define payrolle recruitment agency employee manager director vps svps gender recorded indicate prefer percentage calculate employee number december record hr system gender specify female grade divide total employee system uk ethnic percentage ethnically diverse employee datum cover total number employee internal hr system diversity gsk uk employee population active include fulltimeparttime regulartemporary employee svpvp level director level manager nonactive ie maternity leave paternity leave adoption leave level employee etc exclude puerto ricobase employee agency temporary worker differ ethnic group uk contingent worker define payrolle recruitment agency employee population raceethnic employee blank ethnicity prefer figure category define accord uk census exclude puerto ricobase employee give significant difference ethnic federal reporting guideline composition territory population relative rest percentage calculate employee number december record hr system selfidentifie ethnically diverse divide total employee system ethical standard employee number distinct employee inside outside gsk raise concern speak concern raise disciplinary concern raise independent party integrity line confidentially anonymously concern raise internally employee include current management internal monitoring year prior year datum comprise regular employee exclude contractor open case contingent worker datum include total number distinct employee disciplinary concern raise reporting period employee disciplinary concern raise prior year open case employee discipline number distinct employee datum comprise regular employee exclude contractor policy violation outcome concern raise result contingent worker disciplinary action datum represent case close reporting period include open case disciplinary decision action take year end case close source system reporting criterion end date range time disciplinary action include document warning termination resignation gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue kpi definition method ethical standard breakdown type breakdown type policy violation datum comprise regular employee exclude contractor policy violation employee discipline contingent worker year individual employee subject multiple allegation result policy violation category define disciplinary action case individual count unique category antibribery corruption antibribery corruption employee discipline result policy violation include level cyber security cyber security csir sanction level sanction level sanction final warning termination continuity supply chain supply chain resignation categorise appropriate outcome employee continuity include mediation demotion settlement include count ehs sustainability environment health percentage category outcome type consider safety sustainability disciplinary action represent situation employee employee conduct conflict interest company work solution discrimination expense harassment market germany utilise case management system inappropriate behaviour mandatory training manage case datum retention german market maintain employee relation hr policy case list submit global employee relation team year appeal attendance work capability health end consolidation analysis capability performance external litigation gsk case owner regularly utilise publish datum quality report assist performance system recruitment selection datum accuracy regularly quarterly internal audits conduct restructure programme settlementmutual address outstanding datum discrepancy agreement work arrangement government trade restriction sanction export control product quality good manufacturing practice manufacturing site resilience supply chain quality assurance research development medical practice care welfare treatment animal datum integrity nongxp good laboratory practicesgood clinical practice human biological sample management hbsm nonpromotional engagement nonpromotional engagement patient safety public disclosure regulatory filing safeguard people information asset communication corporate financial information report disclosure crisis continuity management fraud intellectual property privacy loss datum privacy unauthorized access privacy unsecured datum disclosure protection physical asset security security people security place site security productssupply chain sale marketing antitrust commercial practice fund contract sale organisation external expert hcphci transfer value inappropriate managerial direction interaction pagsconsumerpayer group product promotion sample speaker programme tax treasury tax treasury policy violation type fit category specify employee number distinct employee datum comprise regular employee exclude contractor dismiss agree outcome disciplinary concern result contingent worker leave company termination employment voluntary datum represent case close reporting period voluntarily result resignation employee include open case disciplinary decision misconduct action take year end case close source system reporting criterion end date range timing include termination employment resignation document warning number distinct employee datum comprise regular employee exclude contractor outcome disciplinary concern result contingent worker document warning datum represent case close reporting period include open case disciplinary decision action take year end case close source system reporting criterion end date range time disciplinary action include document warning level sanction final warning gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue kpi definition method ethical standard open case await number distinct employee involve datum comprise regular employee exclude contractor investigation investigation disciplinary decision contingent worker disciplinary decision open pende outcome datum represent employee involve disciplinary case year end end reporting period remain open end reporting period include open case disciplinary decision action take year end case close source system reporting criterion end date range timing outcome investigation open await disciplinary action year end capture subsequent reporting period employee percentage active employee andor active employee fulltimeparttime regulartemporary complementary complementary worker complementary worker ie agency worker statement work worker worker complete assign mandatory training curriculum outsource worker etc require complete global mandatory gsk mandatory complete training module learn curriculum call live code comprise module training code protect gsk create inclusive workplace additionally highrisk role geographic region complete additional module focus antibribery corruption percentage calculate training datum december ie train december calculate total number active employee complementary worker assign live code mandatory training complete module divide total population active employee complementary worker assign live code mandatory training employee percentage employee strongly pulse survey issue q q q different believe agree agree question organisation target survey entire employee speak thing speak thing not feel right gsk population gsk reach score calculate average feel right pulse survey score survey survey issue regular fulltime fixedterm contract employee country gsk operate exclude russia ukraine question translate professional service partner language exclude english direct highrisk direct highrisk supplier identify ecovadis programme work direct highrisk supplier supplier achieve yearly basis combination spend help improve operation support sustainability gsk minimum category highrisk country direct journey ecovadi score procurement involve purchase ecovadis external rating provider assess organisation improvement material directly associate theme environment community labour human right ethic plan place production good sustainable procurement total number direct supplier improvement plan place supplier highrisk manage assessment progress supplier commit participate gsk ecovadis programme programme not commence supplier not accept improvement plan place define improvement plan improvement plan implement ongoing improvement plan supplier await reassessment reflect improve score gsk require supplier minimum report supplier improvement plan place ecovadi score improvement plan initiate supplier partner include gsk track ecovadis platform require gsk interact directly supplier ensure corrective action implement ecovadis scorecard datum export ecovadis platform supplier manually adjusted group subsidiary base business relationship gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue kpi definition method product governance total regulatory number regulatory inspection gsk datum represent good manufacturing practise gmpgood inspection entity health authority distribution practice gdp inspection result confirm health authority inspection percentage number regulatory percentage gmpgdp result confirm regulator inspection gsk entity critical percentage calculate total number inspection critical finding finding official action indicate regulator critical finding official action indicate divide official action total number inspection regulator multiply indicate total regulatory number regulatory inspection number regulatory inspection gmpgdp inspection base inspection follow regulator gsk entity fda mhra european regulator national competent authority fdamhraema united states food drug administration inspect behalf ema regulatory body result regulator fda united kingdom uk medicine confirm healthcare product regulatory agency mhra european medicine agency ema national competent authority eea regulator number critical number critical major finding number critical major finding gmpgdp business major finding regulatory inspection gsk entity product base fda mhra european regulator fdamhraema fda uk mhra ema regulator inspect behalf ema regulatory body result regulator confirm total fda regulatory total number regulatory inspection number regulatory inspection gmpgdp business inspection gsk entitie fda product base fda regulatory inspection result confirm fda define inspection onsite paperbase assessment oneoff question exclude fda number fda number observation issue number finding gmpgdp business product observation fda gsk entity base fda regulatory inspection result confirm number fda number warning letter issue number gmpgdp warning letter warn letter fda gsk entity lead enforce regulatory action require total number number external class iiiiii recall number external class iiiiii recall gmpgdp class iiiiii external product break recall type product recall class recall reasonable probability use exposure violative product cause adverse health consequence death class ii recall use exposure violative product cause temporary medically reversible adverse health consequence probability adverse health consequence remote class iii recall use exposure violative product likely cause adverse health consequence datum include recall initiate gsk mandate regulator fda product recall number recall product business unit track recall respective system business class market include recall initiate voluntarily gsk mandate fda fda order statutory authority categorise datum accord business relate pharmaceutical vaccine accord recall type gsk esg performance report march approach access global health environment dei ethical standard product governance appendix appendix continue kpi definition method product governance publicly available trial number trial protocol summary report cumulative number study protocol protocol summary register external face gsk trial register result disclose setup gsk trial register register register wwwgskstudyregistercom gsk internal policy commitment study protocol summary register result disclosure human subject research summary disclose gsk available gsk trial register addition mandatory requirement wwwgskstudyregistercom regulator disclosure protocol registration number represent study initiate protocol register complete study result publicly available trial number trial result summary post summary number generate result summarie external face gsk trial register transparency report derive datum disclosure system disclose wwwgskstudyregistercom gsk business internal policy commitment disclosure human subject research addition mandatory requirement regulator disclosure result summary people disclosure overall turnover overall turnover measure gsk calculate number leaver year percentage employee leave gsk include average permanent headcount internal move gsk employee turnover rate include employee leave company datum include divestment voluntarily involuntarily year include employee divest datum update daily extract gskwide hr platform consumer health business datum base effective date termination termination date termination date day work effective date termination day termination ie follow day employee termination date december include dataset health safety gsk reportable injury illness meet consistent global reporting gsk injury illness meet datum follow criterion list criterion criteria different national regulatory reporting reportable injury affect individual gsk requirement vary world illness include employee worker direct gsk daily fatality supervision incident workrelate outcome involve follow fatality loss consciousness medical treatment aid significant occupational injury occupational illness diagnose physician license healthcare professional day away workrestricte daysjob transfer new case lose time lose time incident result lose time day count day follow incident day away work job transfer restriction employee unable perform routine activity hour work total number hour work hour work calculate base number work day year employee include time employee length average workday number employee site directly supervise agency staff provide gsk human resource gsk esg performance report march independent limit assurance report director gsk plc gskplcgskcommissioneddnvbusinessassuranceservicesuklimiteddnvusorwetoconductalimitedassuranceengagementover selectedinformationpresentedintheesgperformancereportthereportforthereportingyearendeddecember conclusion base procedure perform evidence obtain come attention cause believe select informationisnotfairlystatedandhasnotbeenpreparedinallmaterialrespectsinaccordance withthecriteria thisconclusionrelatesonlytotheselectedinformationandistobereadinthecontextofthis independentlimitedassurancereportinparticulartheinherentlimitationsexplainedoverleaf observation area improvement raise separate report gsk management selectedinformation scope boundary work restrict key performance indicator competence independence includedwithinthereportforthecurrentreportingyeartheselectedinformationliste quality control theenvironmentalsocialandgovernanceesgperformancedataincludedwithinthe reporttheselectedinformationforthereportingyearlistedinappendixof dnv establish policy procedure thisdocument designedtoensurethatdnvitspersonneland theoverallesgperformanceratingscorerelatingtogsksperformanceagainst applicable subject targetsaslistedonpagesofgsksesgperformancereport independence requirement include personnel entity dnv assess theselecte information include assessment risk material maintain independence require misstatementinthereportwehaveusedgsksreportingcriteriaesgdatacollectionand relevant ethical requirement controlprocessesandesgperformanceratingthecriteriaasummaryofwhichcanbe engagement work carry foundonpagesandofthereport independent team sustainability assurance professional multidisciplinary team perform work express conclusion consist professional combination information publish report gsk website current environmental social sustainability reportingperiodorforpreviousperiod assuranceexperience standardandlevelofassurance inherent limitation perform limited assurance engagement accordance international standardonassuranceengagementsisaerevisedassuranceengagementsother audits review historical financial information revise issue assurance engagement subject international auditing assurance standard board standard require inherent limitation selective testing comply ethical requirement plan perform assurance engagement samplingmaynotdetecterrorsfraudorother obtainlimitedassurance irregularitiesnonfinancialdatamaybesubject great inherent uncertainty financial dnvappliesitsownmanagementstandardsandcompliancepoliciesforqualitycontrolin datum give nature method accordance isoiec conformity assessment requirement body calculate estimate determine provide audit certification management system accordingly maintain datatheselectionofdifferentbutacceptable comprehensive system quality control include document policy procedure measurement technique result regardingcompliancewithethicalrequirementsprofessionalstandardsandapplicablelegal different quantification different andregulatoryrequirement entity assurance rely premise procedure perform limited assurance engagement vary nature time datum information provide gsk fromandarelessinextentthanforareasonableassuranceengagementandthelevelof provide good faith dnv assuranceobtainedissubstantiallylowerthantheassurancethatwouldhavebeenobtaine expressly disclaim liability co hadareasonableassuranceengagementbeenperformedweplannedandperformedour responsibility decision person worktoobtaintheevidenceweconsideredsufficienttoprovideabasisforourconclusion entity base assurance sothattheriskofthisconclusionbeinginerrorisreducedbutnotreducedtoverylow statement gsk esg performance report march basisofourconclusion responsibility director require plan perform work order consider riskof material gsk dnv misstatementoftheselectedinformationourworkincludedbutwasnotrestrictedto assessingtheappropriatenessofthecriteriafortheselectedinformation conductinginterviewswithgsksmanagementtoobtainanunderstandingofthekey thedirectorsofgskhavesoleresponsibility processessystemsandcontrolsinplacetogenerateaggregateandreporttheselecte information prepare present select performinglimitedsubstantivetestingonaselectivebasisoftheselectedinformationto information accordance checkthatdatahadbeenappropriatelymeasuredrecordedcollatedandreporte criteria recalculatingtheselectedinformationasestablishedbygskscriteria designingimplementingandmaintaining reviewinginformationprovidedbygsksthirdpartycontractor effective internal control reviewingthattheevidencemeasurementsandthescopeprovidedtousbygskforthe information datum result selectedinformationispreparedinlinewiththecriteria preparation select information readingthereportandnarrativeaccompanyingtheselectedinformationwithinitwith thatisfreefrommaterialmisstatement regardtothecriteria measure report select information base establish criteriaand content statement contain withinthereportandthecriteria ourresponsibilityistoplanandperformour work obtain limited assurance select information preparedinaccordancewiththecriteriaand report gsk form independent limit assurance conclusion base work perform evidence obtain responsibleforthepreparationofthereport dnv business assurance dnvbusinessassuranceservicesuklimite londonuk dnvbusinessassuranceservicesuklimite march ispartofdnvbusinessassuranceaglobal provider certification verification assessment training service help customer build sustainable business performance wwwdnvcoukbetterassurance gsk esg performance report march appendix select information access total number class ii external product recall people reach product reach target total number class iii external product recall people access generic dolutegravir product fda product recall business class voluntary licensing agreement pharmaceutical business estimate child reach synflorixthrough gavi class product recall estimate child reach rotarix gavi class ii product recall estimate girl reach cervarixthrough gavi class iii product recall vaccine business estimate people reach opv unicef class product recall estimate people reach mosquirixrtssas e class ii product recall mvip class iii product recall total people reach register disclose human subject research gsk product dose synflorixvaccine supply gavi million publicly available trial protocol summary register dose rotarix vaccine supply gavi million publicly available trial result summary disclose dose cervarixvaccine supply gavi million ethical standard dose opv vaccine supply unicef million employee cws complete gsk mandatory dose mosquirixrtssa e vaccine supply mvip training million employee believe speak thing albendazole tablet donate help eliminate lymphatic filariasis feel right million direct highrisk supplier achieve ecovadisscore albendazole tablet donate help treat intestinal worm million improvement plan place community investment employee leave gsk employment misconduct total community investment million month cash million employee concern raise include current product inkind million year prior year open case time million employee discipline policy violation management cost million breakdown type policy violation people reach patient assistance program employee conduct value gsk medicine vaccine provide patient sale marketing assistance program foundation million usd product quality global health health security safeguard people information asset number asset progress global health pipeline employee relation address priority disease research development medical practice inclusion diversity antibribery corruption ethnic diversity break svpvp director manager computer data breach security employee eh sustainability ethnically diverse total employee dismiss agree leave company uk ethnic diversity break svpvp director manager voluntarily result misconduct employee ethnically diverse total document warning open case await investigation disciplinary decision year gender diversity break svpvp director manager end employee total woman management people disclosures number fatality employee complementary worker governance gsk direct supervision product governance fatality contractor gsk direct supervision regulatory inspection reportable injury lose time total regulatory inspection health authority reportable illness lose time inspection regulator critical finding lose time reportable injury rate official action indicate lose time reportable illness rate total regulatory inspection fdamhraema regulator reportable injury lose time number criticalmajor finding fdamhraema regulator reportable illness lose time total fda regulatory inspection reportable injury rate number fda observation reportable illness rate number fda warning letter reportable injury illness rate hour work product recall overall turnover total product recall total number class external product recall gsk esg performance report march iinnddeeppeennddeenntt lliimmiitteedd aassssuurraannccee rreeppoorrtt ttoo tthhee ddiirreeccttoorrss ooff ggsskk ppllcc independent limited assurance report deloitte llp directors gsk plc select environmental social governance esg metric select information annual report account environmental social governance esg performance report year end december wwhhaatt wwee ffoouunndd oouurr aassssuurraannccee ccoonncclluussiioonn base procedure describe report evidence obtain come attention cause believe select information list indicate annual report account esg performance report prepare material respect accordance applicable criterion define basis reporting prepare publish gsk plc esg resources gsk wwhhaatt wwee llooookkeedd aatt ssccooppee ooff oouurr wwoorrkk rreevviisseedd aass ppeerr tthhee ootthheerr mmaatttteerrss sseeccttiioonn bbeellooww gsk plc engage provide independent limited assurance accordance international standard assurance engagement revise assurance engagement audits review historical financial information isae revise international standard assurance engagement assurance engagement greenhouse gas statement isae issue international auditing assurance standard board iaasb agree term engagement select information scope engagement list indicate annual report account esg performance report follow select information unit assure value scope emission tonne co e scope emission market base tonne co e scope emission location tonne co e base total scope market base tonne co e emission total energy operation gwh purchase renewable electricity gwh onsite renewably generate gwh electricity emission use propellant tonne co e base inhaler patient total water use high water risk cubic metre site total wastewater discharge cubic metre total water use cubic metre gsk esg performance report march select information list tableneed read understand applicable criterion set basis report esg resource gsk iinnhheerreenntt lliimmiittaattiioonnss ooff tthhee sseelleecctteedd iinnffoorrmmaattiioonn obtain limited assurance preparation select information accordance applicable criterion inherent limitation exist assurance engagement internal control structure matter effective eliminate possibility fraud error irregularity occur remain undetected use selective testing engagement guarantee error irregularity present detect applicable criterion define gsk plc basis reporting nature select information absence consistent external standard allow different acceptable measurement methodology adopt result variance entity adopt measurement methodology impact comparability select information report different organisation year year organisation methodology develop ootthheerr mmaatttteerrss initial select information scope engagement include waste metric define course work clear unable obtain evidence need support conclusion respect waste metric describe management conclude significant remediation require measurement report waste metric ask remove scope engagement waste metric define total circular waste total waste generate tonne total waste recover circular route tonne total waste send landfill tonne ddiirreeccttoorrss rreessppoonnssiibbiilliittiieess director responsible prepare annual report account complie requirement company act satisfied annual report account esg performance report take fair balanced understandable director responsible making available necessary record correspondence information explanation necessary allow successful completion service select andor establish suitable criterion prepare select information measure report select information accordance applicable criterion design implement maintain internal process control information relevant preparation select information free material misstatement fraud error take reasonable step prevention detection fraud irregularity gsk esg performance report march oouurr rreessppoonnssiibbiilliittiieess responsible independently express conclusion base assurance procedure come attention cause believe select information set prepared material respect accordance applicable criterion year end december oouurr iinnddeeppeennddeennccee aanndd ccoommppeetteennccee conducting engagement comply independence requirement frc ethical standard icaew code ethic icaew code found fundamental principle integrity objectivity professional competence care confidentiality professional behaviour apply international standard quality management isqm issue financial reporting council accordingly maintain comprehensive system quality include document policy procedure compliance ethical requirement professional standard applicable legal regulatory requirement wwhhaatt wwee ddiidd kkeeyy pprroocceedduurreess require plan perform work address area identify material misstatement description activity undertake respect select information likely arise procedure perform base professional judgement carry limited assurance engagement description activity undertake respect select information perform follow procedure perform enquire interview management understand applicable criterion apply preparation select information understand internal control quantification process datum prepare select information methodology gathering qualitative information process prepare report select information inspect document relate select information include board committee minute understand level management awareness oversight select information consider risk material misstatement select information include analytical review procedure perform procedure select information include recalculation relevant formulae manual calculation assessment datum appropriately consolidated perform procedure underlie datum sample basis assess datum collect report accordance applicable criterion include verify source documentation perform procedure select information include assess management assumption estimate perform site visit selection operational site understand process place read report narrative accompany select information regard applicable criterion consistency finding accumulate misstatement control deficiency identify assess material procedure perform limited assurance engagement vary nature time extent reasonable assurance engagement consequently level assurance gsk esg performance report march obtain limited assurance engagement substantially low assurance obtain reasonable assurance engagement perform uussee ooff oouurr rreeppoorrtt report solely director gsk plc accordance isae revise isae agree term engagement work undertake state director gsk plc matter agree state report purpose assume accept responsibility liability respect report party gsk plc director gsk plc acknowledge directors gsk plc choose report publicly available wish access affect extend purpose basis responsibility full extent permit law accept assume responsibility gsk plc director gsk plc body work report conclusion form ddeellooiittttee llllpp london uk march gsk esg performance report march